Evozyne Stock

Evozyne, founded by Paragon Biosciences, is dedicated to leveraging the principles of evolution and advanced computational techniques to create innovative protein systems. The company focuses on solving significant problems in human health and environmental sustainability through its cutting-edge approach to protein engineering. Evozyne's technology harnesses generative AI to simulate evolutionary processes, enabling the design of proteins with exceptional functionality and adaptability. This method allows for the exploration of vast design spaces, optimizing multiple parameters simultaneously to develop high-performance proteins. Evozyne's products include therapeutic proteins such as IgG protease enzymes and a portfolio of CRISPR gene editors, which aim to revolutionize treatments for currently untreatable diseases. Evozyne collaborates with industry giants like NVIDIA and Takeda to enhance its protein engineering capabilities. These partnerships have led to significant advancements, such as the development of therapeutic biologics with superior catalytic activity and enzymes with enhanced thermostability for CO2 capture. These innovations underscore Evozyne's commitment to accelerating the development of life-changing therapies and contributing to a healthier world.